Amphastar Pharmaceuticals Inc

Amphastar insider sells 1,033 shares at $18.18 while the company expands a $50 million share‑repurchase, showing routine liquidity moves, not distress.

Amphastar CFO’s modest 1,973‑share sale amid a $50 M buyback shows no bearish trend—investors can trust the company’s solid pipeline and steady P/E.

Amphastar CFO William Peters’ bulk RSU purchase signals bullish outlook—learn how insider buying could spark a stock rebound.

Investor insight: Amphastar’s senior EVP Zhou Rong’s March 2026 share buy and tax‑covering sell signal confidence in the company’s pipeline, offering a bullish sign amid recent volatility.

Amphastar EVP Liawatidewi Yakob’s recent RSU buy and small share sale shows a mix of long‑term confidence and short‑term tax‑planning, hinting at potential upside in a near‑bottom stock.

Amphastar CEO’s RSU buy signals long‑term confidence despite a steep 34% decline, hinting at future upside if the drug pipeline succeeds.

Amphastar CEO Jack Zhang’s March sale sparks 178 % social buzz—was it a tax move or a sign of future product confidence? Learn the real impact.

Insightful look at Zhou Rong’s March 4 insider sale at Amphastar Pharm—what it signals amid a 4.3% weekly slide and exec‑sell trends.